Yancy William S, Westman Eric C, McDuffie Jennifer R, Grambow Steven C, Jeffreys Amy S, Bolton Jamiyla, Chalecki Allison, Oddone Eugene Z
Center for Health Services Research in Primary Care, Department of Veterans Affairs Medical Center, Durham, North Carolina, USA.
Arch Intern Med. 2010 Jan 25;170(2):136-45. doi: 10.1001/archinternmed.2009.492.
Two potent weight loss therapies, a low-carbohydrate, ketogenic diet (LCKD) and orlistat therapy combined with a low-fat diet (O + LFD), are available to the public but, to our knowledge, have never been compared.
Overweight or obese outpatients (n = 146) from the Department of Veterans Affairs primary care clinics in Durham, North Carolina, were randomized to either LCKD instruction (initially, <20 g of carbohydrate daily) or orlistat therapy, 120 mg orally 3 times daily, plus low-fat diet instruction (<30% energy from fat, 500-1000 kcal/d deficit) delivered at group meetings over 48 weeks. Main outcome measures were body weight, blood pressure, fasting serum lipid, and glycemic parameters.
The mean age was 52 years and mean body mass index was 39.3 (calculated as weight in kilograms divided by height in meters squared); 72% were men, 55% were black, and 32% had type 2 diabetes mellitus. Of the study participants, 57 of the LCKD group (79%) and 65 of the O + LFD group (88%) completed measurements at 48 weeks. Weight loss was similar for the LCKD (expected mean change, -9.5%) and the O + LFD (-8.5%) (P = .60 for comparison) groups. The LCKD had a more beneficial impact than O + LFD on systolic (-5.9 vs 1.5 mm Hg) and diastolic (-4.5 vs 0.4 mm Hg) blood pressures (P < .001 for both comparisons). High-density lipoprotein cholesterol and triglyceride levels improved similarly within both groups. Low-density lipoprotein cholesterol levels improved within the O + LFD group only, whereas glucose, insulin, and hemoglobin A(1c) levels improved within the LCKD group only; comparisons between groups, however, were not statistically significant.
In a sample of medical outpatients, an LCKD led to similar improvements as O + LFD for weight, serum lipid, and glycemic parameters and was more effective for lowering blood pressure.
clinicaltrials.gov Identifier: NCT00108524.
两种有效的减肥疗法可供公众使用,即低碳水化合物生酮饮食(LCKD)和奥利司他疗法联合低脂饮食(O + LFD),但据我们所知,这两种疗法从未被比较过。
来自北卡罗来纳州达勒姆退伍军人事务部初级保健诊所的超重或肥胖门诊患者(n = 146)被随机分为LCKD指导组(最初,每日碳水化合物摄入量<20 g)或奥利司他治疗组,口服120 mg,每日3次,加上在48周的小组会议上进行低脂饮食指导(脂肪提供的能量<30%,每日能量 deficit 500 - 1000 kcal)。主要结局指标为体重、血压、空腹血脂和血糖参数。
平均年龄为52岁,平均体重指数为39.3(计算方法为体重千克数除以身高米数的平方);72%为男性,55%为黑人,32%患有2型糖尿病。在研究参与者中,LCKD组的57名(79%)和O + LFD组的65名(88%)在48周时完成了测量。LCKD组(预期平均变化,-9.5%)和O + LFD组(-8.5%)的体重减轻相似(比较P = 0.60)。LCKD对收缩压(-5.9 vs 1.5 mmHg)和舒张压(-4.5 vs 0.4 mmHg)的影响比O + LFD更有益(两项比较P均<0.001)。两组内高密度脂蛋白胆固醇和甘油三酯水平的改善相似。仅O + LFD组的低密度脂蛋白胆固醇水平有所改善,而仅LCKD组的血糖、胰岛素和糖化血红蛋白A1c水平有所改善;然而,组间比较无统计学意义。
在一组门诊患者样本中,LCKD在体重、血脂和血糖参数方面与O + LFD导致相似的改善,并且在降低血压方面更有效。
clinicaltrials.gov标识符:NCT00108524。